- €37.71bn
- €67.21bn
- €45.58bn
Annual income statement for Bayer AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 44,081 | 50,739 | 47,637 | 46,606 | 45,575 |
| Cost of Revenue | |||||
| Gross Profit | 27,265 | 30,868 | 27,888 | 25,336 | 26,778 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 40,728 | 43,727 | 47,025 | 46,677 | 46,652 |
| Operating Profit | 3,353 | 7,012 | 612 | -71 | -1,077 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 2,046 | 4,670 | -1,621 | -2,334 | -3,129 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1,022 | 4,166 | -2,942 | -2,546 | -3,595 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 1,000 | 4,150 | -2,941 | -2,552 | -3,620 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1,000 | 4,150 | -2,941 | -2,552 | -3,620 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 4.39 | 8.12 | 2.52 | 2.03 | 5.91 |
| Dividends per Share |